Analyst Price Target is $137.67
▲ +221.05% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Turning Point Therapeutics in the last 3 months. The average price target is $137.67, with a high forecast of $175.00 and a low forecast of $75.00. The average price target represents a 221.05% upside from the last price of $42.88.
Current Consensus is
The current consensus among 9 polled investment analysts is to buy stock in Turning Point Therapeutics. This Buy consensus rating has held steady for over two years.
Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.